Bayesian joint modeling of ordinal longitudinal measurements and competing risks survival data for analysing Tehran Lipid and Glucose Study
In this paper, joint modeling of longitudinal ordinal measurements and time to some events of interest as competing risks is discussed. For this purpose, a latent variable sub-model under linear mixed-effects assumption is considered for modeling ordinal longitudinal measurements. Also, a Weibull cause-specific sub-model is used to model competing risks data. These two sub-models are simultaneously considered in a unique model by a shared parameter model framework. Some simulation studies are performed for illustration of the proposed approaches; also, the proposed approaches are used for analyzing 15 years of lipid and glucose follow-up study in Tehran.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Journal of biopharmaceutical statistics - 30(2020), 4 vom: 03. Juli, Seite 689-703 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baghfalaki, Taban [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bayesian paradigm |
|---|
| Anmerkungen: |
Date Completed 02.08.2021 Date Revised 02.08.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10543406.2020.1730876 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307210154 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307210154 | ||
| 003 | DE-627 | ||
| 005 | 20231225125050.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10543406.2020.1730876 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1024.xml |
| 035 | |a (DE-627)NLM307210154 | ||
| 035 | |a (NLM)32129702 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baghfalaki, Taban |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bayesian joint modeling of ordinal longitudinal measurements and competing risks survival data for analysing Tehran Lipid and Glucose Study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.08.2021 | ||
| 500 | |a Date Revised 02.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In this paper, joint modeling of longitudinal ordinal measurements and time to some events of interest as competing risks is discussed. For this purpose, a latent variable sub-model under linear mixed-effects assumption is considered for modeling ordinal longitudinal measurements. Also, a Weibull cause-specific sub-model is used to model competing risks data. These two sub-models are simultaneously considered in a unique model by a shared parameter model framework. Some simulation studies are performed for illustration of the proposed approaches; also, the proposed approaches are used for analyzing 15 years of lipid and glucose follow-up study in Tehran | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bayesian paradigm | |
| 650 | 4 | |a competing risks | |
| 650 | 4 | |a joint modeling | |
| 650 | 4 | |a latent variable | |
| 650 | 4 | |a linear mixed model | |
| 650 | 4 | |a longitudinal data | |
| 650 | 4 | |a ordinal data | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Kalantari, Shiva |e verfasserin |4 aut | |
| 700 | 1 | |a Ganjali, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Hadaegh, Farzad |e verfasserin |4 aut | |
| 700 | 1 | |a Pahlavanzadeh, Bagher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biopharmaceutical statistics |d 1991 |g 30(2020), 4 vom: 03. Juli, Seite 689-703 |w (DE-627)NLM012811432 |x 1520-5711 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2020 |g number:4 |g day:03 |g month:07 |g pages:689-703 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10543406.2020.1730876 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2020 |e 4 |b 03 |c 07 |h 689-703 | ||